Published in J Infect Dis on April 03, 2012
Rising to the challenge: new therapies for tuberculosis. Trends Microbiol (2013) 1.04
Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. PLoS One (2013) 1.01
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res (2014) 0.90
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther (2013) 0.89
Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci (2014) 0.85
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis (2015) 0.85
Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis. EBioMedicine (2015) 0.84
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop (2014) 0.80
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int (2015) 0.79
Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis. EBioMedicine (2015) 0.75
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Sci Rep (2017) 0.75
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum (2009) 3.58
Understanding latent tuberculosis: a moving target. J Immunol (2010) 2.95
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol (2011) 2.59
Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.66
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol (2009) 1.54
Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol (2009) 1.47
Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect Immun (2004) 1.44
New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm (2000) 1.24
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.21
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol (2007) 1.18
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant (2008) 1.05
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Extensively drug-resistant tuberculosis. Lancet Infect Dis (2008) 3.21
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 2.13
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol (2004) 1.96
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med (2010) 1.91
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Plasmids and rickettsial evolution: insight from Rickettsia felis. PLoS One (2007) 1.85
Molecular epidemiology of tuberculosis in a low- to moderate-incidence state: are contact investigations enough? Emerg Infect Dis (2002) 1.64
Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun (2003) 1.63
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun (2005) 1.58
A novel copper-responsive regulon in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.56
Short report: modulation of Mycobacterium tuberculosis infection by Plasmodium in the murine model. Am J Trop Med Hyg (2004) 1.54
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cell Microbiol (2004) 1.48
Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother (2006) 1.48
Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol (2009) 1.47
Evidence that the Streptomyces developmental protein WhiD, a member of the WhiB family, binds a [4Fe-4S] cluster. J Biol Chem (2004) 1.42
Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol Microbiol (2010) 1.42
Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect Immun (2004) 1.41
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis (2008) 1.40
"Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates. Mol Cell (2010) 1.37
Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One (2009) 1.37
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Epidemiology and challenges to the elimination of global tuberculosis. Clin Infect Dis (2010) 1.36
Phosphate depletion: a novel trigger for Mycobacterium tuberculosis persistence. J Infect Dis (2009) 1.35
Deletion of Mycobacterium tuberculosis sigma factor E results in delayed time to death with bacterial persistence in the lungs of aerosol-infected mice. Infect Immun (2003) 1.34
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med (2005) 1.31
Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother (2007) 1.29
An anomalous type IV secretion system in Rickettsia is evolutionarily conserved. PLoS One (2009) 1.26
Extrapulmonary dissemination of Mycobacterium bovis but not Mycobacterium tuberculosis in a bronchoscopic rabbit model of cavitary tuberculosis. Infect Immun (2008) 1.26
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
Characterization of the Mycobacterium tuberculosis sigma factor SigM by assessment of virulence and identification of SigM-dependent genes. Infect Immun (2006) 1.23
Pathogenesis of central nervous system tuberculosis. Curr Mol Med (2009) 1.22
Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med (2013) 1.20
Isolation of acid-inducible genes of Mycobacterium tuberculosis with the use of recombinase-based in vivo expression technology. Infect Immun (2003) 1.20
A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imaging. EJNMMI Res (2013) 1.17
The Mycobacterium tuberculosis SigD sigma factor controls the expression of ribosome-associated gene products in stationary phase and is required for full virulence. Cell Microbiol (2005) 1.16
Characterization of a novel cell wall-anchored protein with carboxylesterase activity required for virulence in Mycobacterium tuberculosis. J Biol Chem (2007) 1.16
Computer-aided detection and quantification of cavitary tuberculosis from CT scans. Med Phys (2013) 1.14
Roles of SigB and SigF in the Mycobacterium tuberculosis sigma factor network. J Bacteriol (2007) 1.14
The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs. J Infect Dis (2010) 1.13
Field evaluation of a rapid immunochromatographic test for tuberculosis. J Clin Microbiol (2002) 1.12
Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.12
Mycobacterium tuberculosis invasion and traversal across an in vitro human blood-brain barrier as a pathogenic mechanism for central nervous system tuberculosis. J Infect Dis (2006) 1.11
Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system. J Infect Dis (2008) 1.11
Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure (2012) 1.10
Characterization of the role of the divalent metal ion-dependent transcriptional repressor MntR in the virulence of Staphylococcus aureus. Infect Immun (2003) 1.10
Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Infect Dis (2007) 1.10
Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother (2005) 1.09
The two-domain LysX protein of Mycobacterium tuberculosis is required for production of lysinylated phosphatidylglycerol and resistance to cationic antimicrobial peptides. PLoS Pathog (2009) 1.09
Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues. J Infect Dis (2006) 1.09
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother (2007) 1.09
Comparison of C(18)-carboxypropylbetaine and standard N-acetyl-L-cysteine-NaOH processing of respiratory specimens for increasing tuberculosis smear sensitivity in Brazil. J Clin Microbiol (2002) 1.09
Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat Protoc (2013) 1.06
Regulation of the expression of whiB1 in Mycobacterium tuberculosis: role of cAMP receptor protein. Microbiology (2006) 1.06
Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One (2012) 1.04
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A (2012) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Rising to the challenge: new therapies for tuberculosis. Trends Microbiol (2013) 1.04
Role of stress response sigma factor SigG in Mycobacterium tuberculosis. J Bacteriol (2007) 1.03
The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. PLoS One (2010) 1.03
Mycobacterium tuberculosis SigF regulates genes encoding cell wall-associated proteins and directly regulates the transcriptional regulatory gene phoY1. J Bacteriol (2007) 1.03
13[C]-urea breath test as a novel point-of-care biomarker for tuberculosis treatment and diagnosis. PLoS One (2010) 1.02
Louse- and flea-borne rickettsioses: biological and genomic analyses. Vet Res (2008) 1.01
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother (2010) 1.01
Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J Biol Chem (2012) 1.01
Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One (2012) 0.99
Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Mol Microbiol (2009) 0.99
Role of Mycobacterium tuberculosis pknD in the pathogenesis of central nervous system tuberculosis. BMC Microbiol (2012) 0.98
Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect Immun (2004) 0.97